Amgen (AMGN)
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-08
$367.99-0.03%
Close 2026-07-08 · 1-day change
Reading AMGN? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track AMGN free→NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-08
Reading AMGN? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track AMGN free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment is characterized as a durable compounder with a focus on long-term growth through innovation. The current thesis state is intact, as recent financial results are solid and management remains stable.
The valuation is stretched, indicating that the market has priced in some expectations for future performance. However, AMGN is seen as cheap compared to its peers, suggesting there may be an expectations gap.
Fundamentals are likely to remain strong, given the recent revenue growth and management's focus on innovation. There is a moderate risk of missing future guidance, but the current low miss probability suggests stability.
The thesis hinges on sector performance, particularly the results of major peers like LLY, JNJ, and ABBV. If these companies continue to perform well, AMGN may benefit from positive momentum; however, any negative guidance from them could impact AMGN adversely.
Over the next 1 to 3 years, AMGN's performance will depend on its ability to maintain growth and navigate sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the read. However, regulatory issues threaten long-term growth through innovation.
as of 2026-07-08
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Approvals are important to complete the ChemoCentryx deal. This affects Amgen's growth plans.
Confirms:All needed approvals for the ChemoCentryx deal are granted.
Disproves:Regulators deny the deal or add major conditions.
Why it matters: Finalizing this acquisition could enhance Amgen's portfolio and revenue growth. It shows commitment to long-term growth.
Confirms:The acquisition is done and gets the needed approvals.
Disproves:The acquisition does not get approvals or is delayed too long.
Why it matters: Good trial results could help Amgen in the atopic dermatitis market.
Confirms:Positive Phase 3 trial results for KHK4083 are announced.
Disproves:Trial results show KHK4083 fails to meet primary endpoints.
Why it matters: Earnings results will show if Amgen continues its growth trend. This is crucial for investor confidence.
Confirms one read:Earnings report shows revenue growth exceeding 5% year over year.
Confirms the other:Earnings report shows revenue growth below 0% year over year.
Why it matters: Good integration can help Amgen grow with new therapies. It shows how well Amgen handles acquisitions.
Confirms:Management gives a good update on the deal and its benefits.
Disproves:Management reports issues in the deal that may delay benefits.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.